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Abstract
Following the adoption of Regulation (EU) 2015/2283 of the European Parliament and of the Council
on novel foods, the European Commission requested EFSA to update and develop scientiﬁc and
technical guidance for the preparation and presentation of applications for authorisation of novel
foods. This guidance presents a common format for the organisation of the information to be
presented in order to assist the applicant in preparing a well-structured application to demonstrate the
safety of the novel food. The application should be comprehensive and complete. This guidance
outlined the data needed for the safety assessments of novel foods. Requirements which should be
covered in all applications relate to the description of the novel food, production process,
compositional data, speciﬁcation, proposed uses and use levels, and anticipated intake of the novel
food. Further sections on the history of use of the novel food and/or its source, absorption,
distribution, metabolism, excretion, nutritional information, toxicological information and allergenicity
should be considered by the applicant by default. If not covered in the application, this should be
justiﬁed. The applicant should integrate the data presented in the different sections to provide their
overall considerations on how the information supports the safety of the novel food under the
proposed conditions of use. Where potential health hazards have been identiﬁed, they should be
discussed in relation to the anticipated intakes of the novel food and the proposed target populations.
On the basis of the information provided, EFSA will assess the safety of the novel food under the
proposed conditions of use.
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Summary
Following the adoption of Regulation (EU) 2015/2283 of the European Parliament and of the
Council on novel foods, the European Commission requested the European Food Safety Authority
(EFSA) to update and develop scientiﬁc and technical guidance for the preparation and presentation of
applications for authorisation of novel foods.
This guidance presents a common format for the organisation of the information to be presented in
order to assist the applicant in the preparation of a well-structured application to demonstrate the
safety of the novel food. Adherence to this format will facilitate easy access to information and
scientiﬁc data in applications to help EFSA to carry out its evaluation and to deliver its scientiﬁc opinion
in an effective and consistent way. This guidance is also intended to provide the type and quality of
information EFSA needs to conclude whether or not the novel food is safe under the proposed
conditions of use.
This guidance outlines the data needed to carry out the safety assessments of novel foods.
Requirements which should be covered in all applications relate to the description of the novel food,
production process, compositional data, speciﬁcation, proposed uses and use levels, and anticipated
intake of the novel food. Further sections on the history of use of the novel food and/or its source,
absorption, distribution, metabolism, excretion, nutritional information, toxicological information and
allergenicity should be considered by the applicant by default. If not covered in the application, this
should be justiﬁed. Duplication of animal testing should be avoided, where possible.
The applicant should integrate the data presented in the different sections to provide their overall
considerations on how the information supports the safety of the novel food under the proposed
conditions of use.
Where potential health hazards have been identiﬁed (e.g. on the basis of the composition of the
novel food, its production process, its history of use, results from animal or human studies), they
should be discussed in relation to the anticipated intakes of the novel food and the proposed target
populations.
On the basis of the information provided, EFSA will assess the safety of the novel food under the
proposed conditions of use.
The guidance document was subject to public consultation (from 18 February to 21 April 2016) and
a stakeholder meeting (11 April 2016) before ﬁnalisation.
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Background as provided by the European Commission
On 25 November 2015, the European Parliament and the Council adopted the Regulation of the
European Parliament and of the Council on novel foods.1
The Regulation requires that all applications for the authorisation of novel foods shall be submitted
to the Commission who may then request a risk assessment from the European Food Safety Authority
(EFSA). In assessing the safety of novel foods, EFSA shall, where appropriate, consider the following:
1) whether the novel food concerned is as safe as food from a comparable food category already
existing on the market within the Union;
2) whether the composition of the novel food and the conditions of its use do not pose a safety
risk to human health in the Union;
3) a novel food, which is intended to replace another food, does not differ from that food in such a
way that its normal consumption would be nutritionally disadvantageous for the consumer.
The Regulation also introduces a special procedure for safety assessment for traditional foods from
third countries, based on a history of safe food use. In this case, a notiﬁcation for the placing on the
market of a traditional food from a third country is sent to the Commission who forwards it to all
the Member States and EFSA. A Member State or EFSA may submit duly reasoned safety objections on
the placing on the market of the notiﬁed food. In this latter case, the applicant may transform the
notiﬁcation into an application, for which a safety evaluation will be requested from EFSA. In assessing
the safety of these types of novel foods, EFSA shall, where appropriate, consider the following:
1) whether the history of safe food use in a third country is substantiated by reliable data
submitted by the applicant;
2) whether the composition of the food and the conditions of its use do not pose a safety risk to
human health in the Union;
3) where the traditional food from the third country is intended to replace another food, whether
it does not differ from that food in such a way that its normal consumption would be
nutritionally disadvantageous for the consumer.
The Commission shall adopt implementing rules on administrative and scientiﬁc requirements for
the preparation and the presentation of the applications for novel foods, as well as for the notiﬁcations
and applications for traditional foods from third countries for the scientiﬁc assessment, respectively, in
accordance with Article 13 and Article 20 of the Regulation. These implementing measures need to be
complemented with scientiﬁc and technical guidance regarding the information that needs to be
submitted by the applicants. In this context, the current Commission Recommendation 97/618/EC,2
which is in place for the additional safety assessment of the novel food applications under the current
rules (Regulation (EC) No 258/973), should serve as the basis for updating the guidance on
preparation and presentation of applications for novel foods.
Terms of Reference as provided by the European Commission
In accordance with Article 29 of Regulation (EC) No 178/2002, the European Commission asks
EFSA to update and develop scientiﬁc and technical guidance for the preparation and presentation of
applications for authorisation of novel foods, and to develop scientiﬁc and technical guidance for
notiﬁcations and applications for authorisation of Traditional Foods from third countries.
Objectives
This guidance presents a common format for the organisation of the information to be presented in
order to assist the applicant in the preparation of a well-structured application to demonstrate the
safety of the novel food. Adherence to this format will facilitate easy access to information and
scientiﬁc data in applications to help EFSA to carry out its evaluation and to deliver its scientiﬁc opinion
in an effective and consistent way.
1 Regulation (EU) 2015/2283 of the European Parliament and of the Council on novel foods, amending Regulation (EU) No 1169/2011
of the European Parliament and of the Council and repealing Regulation (EC) No 258/97 of the European Parliament and of the
Council and Commission Regulation (EC) No 1852/2001 (2013/0435 (COD). OJ L 327, 11.12.2015, p. 1–22.
2 OJ L 253, 16.9.1997, p. 1.
3 OJ L 43, 14.2.1997, p. 1.
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This guidance is also intended to provide the type and quality of information EFSA needs to
conclude whether or not the novel food is safe under the proposed conditions of use. The
requirements for preparing and presenting a dossier for the notiﬁcation of a traditional food from a
third country are dealt with by a separate guidance document EFSA NDA Panel (2016a).
It is intended that the guidance will be kept under review and it will be further updated as
appropriate in the light of experience gained from the evaluation of novel food applications.
Scope
The guidance presented in this document is for preparing and presenting applications for
authorisation of a novel food under Article 10 of Regulation (EU) 2015/2283.
A separate EFSA guidance document is available to assist applicants in preparing and presenting a
notiﬁcation dossier for a traditional food from a third country under Article 14 of Regulation (EU) 2015/2283
(EFSA NDA Panel, 2016a). The latter document speciﬁcally addresses the data required to substantiate
the ‘history of safe food use in third country’ of a traditional food, as deﬁned by Article 3 of Regulation
(EU) 2015/2283. Under the notiﬁcation procedure, Regulation (EU) 2015/2283 foresees that a Member
State or EFSA may submit to the Commission duly reasoned safety objections to the placing on the
market within the Union of the traditional food concerned. In such cases, the present guidance should
also serve applicants in preparing and presenting an application under Article 16 of Regulation (EU)
2015/2283, where the application concerns data other than those on the ‘history of safe food use in a
third country’.
Deﬁnitions
As per Article 3, paragraph 2 of Regulation (EU) 2015/2283, the following deﬁnition applies:
(a) ‘Novel food’ means any food that was not used for human consumption to a signiﬁcant degree
within the Union before 15 May 1997 irrespective of the dates of accession of Member States to the
Union and that falls under at least one of the following categories:
i) food with a new or intentionally modiﬁed molecular structure, where that structure was not
used as, or in, a food within the Union before 15 May 1997;
ii) food consisting of, isolated from or produced from microorganisms, fungi or algae;
iii) food consisting of, isolated from or produced from material of mineral origin;
iv) food consisting of, isolated from or produced from plants or their parts, except when the
food has a history of safe food use within the Union and is consisting of, isolated from or
produced from a plant or a variety of the same species obtained by:
– traditional propagating practices which have been used for food production within the
Union before 15 May 1997; or
– non-traditional propagating practices which have not been used for food production within
the Union before 15 May 1997, where those practices do not give rise to signiﬁcant
changes in the composition or structure of the food affecting its nutritional value,
metabolism or level of undesirable substances;
v) food consisting of, isolated from or produced from animals or their parts, except for animals
obtained by traditional breeding practices which have been used for food production within
the Union before 15 May 1997 and the food from those animals has a history of safe food
use within the Union;
vi) food consisting of, isolated from or produced from cell culture or tissue culture derived from
animals, plants, microorganisms, fungi or algae;
vii) food resulting from a production process not used for food production within the Union
before 15 May 1997, which gives rise to signiﬁcant changes in the composition or structure of
a food, affecting its nutritional value, metabolism or level of undesirable substances;
viii) food consisting of engineered nanomaterials as deﬁned in point (f) of Article 3, paragraph 2
of Regulation (EU) 2015/2283;
ix) vitamins, minerals and other substances used in accordance with Directive 2002/46/EC,
Regulation (EC) No 1925/2006 or Regulation (EU) No 609/2013, where:
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– a production process not used for food production within the Union before 15 May 1997
has been applied as referred to in point (a) (vii) of this paragraph; or
– they contain or consist of engineered nanomaterials;
x) food used exclusively in food supplements within the Union before 15 May 1997, where it is
intended to be used in foods other than food supplements as deﬁned in point (a) of Article 2
of Directive 2002/46/EC.
General principles
1) This document should be read in conjunction with Regulation (EU) 2015/2283 of the European
Parliament and of the Council as regards novel foods and the current and future European
Union (EU) guidelines and provisions. In addition, several guidance documents from EFSA are of
relevance for the preparation of novel food applications. They are listed throughout the present
document. Over time, new guidance documents will be developed which may be of relevance
for novel food applications. Other EFSA guidance documents, for example, those from the EFSA
Scientiﬁc Committee or the Panel on Food Additives and Nutrient Sources Added to Food might
be applicable in speciﬁc cases. Applicants are therefore advised to consult the EFSA webpage
and consider the most up-to-date versions of the available and applicable guidance documents.
2) The term ‘application’ hereafter means a stand-alone dossier containing the information and the
scientiﬁc data submitted for the safety assessment of a novel food.
3) It is the duty of the applicant to provide all of the available (proprietary, conﬁdential and
published) scientiﬁc data (including both data in favour and not in favour) that are pertinent to
the safety of the novel food. As such, an application to demonstrate the safety of the novel
food should be comprehensive and complete.
4) The identiﬁcation of data pertinent to the safety of the novel food should be performed and
documented in order to demonstrate that the application covers the complete information
available on the novel food. Information on the search strategy, including the sources used to
retrieve pertinent data (databases, other sources), the terms and limits used (e.g. publication
dates, publication types, languages, population, default tags) should be provided. Where
applicable, the published literature should be reviewed by taking into account systematic review
principles (EFSA, 2010). Full study reports should be provided if available.
5) This guidance presents a common format for the organisation of the information in order to
assist applicants in the preparation of well-structured applications. Adherence to this format will
facilitate easy access to information and scientiﬁc data in applications to help the EFSA Panel on
Dietetic Products, Nutrition and Allergies (NDA Panel) to carry out its evaluation and to deliver
its scientiﬁc opinion in an effective and consistent way.
6) The structure of the application should follow the sections presented in this guidance. The
information required on the identity of the novel food (Section 2.2), production process
(Section 2.3), compositional data (Section 2.4), speciﬁcations (Section 2.5), and proposed uses
and use levels and anticipated intake of the novel food (Section 2.7) constitute the minimum
requirements which must be fulﬁlled in all applications. Further sections on the history of use of
the novel food and/or of its source (Section 2.6), absorption, distribution, metabolism and
excretion (Section 2.8), nutritional information (Section 2.9), toxicological information
(Section 2.10) and allergenicity (Section 2.11) should be considered by the applicant. If not
covered in the application, this should be justiﬁed.
7) The applicant should provide their considerations at the end of individual sections on how the
information supports the safety of the novel food under the proposed conditions of use.
Uncertainties should be addressed, and a critical appraisal on data both in favour and not in
favour, of the safety of the novel food should be provided.
8) Analyses/tests should be performed in a competent facility that can certify the data. Quality
systems in place for control/documentation should be indicated. Information on the
accreditation of involved facilities and certiﬁcates of analyses should be provided. Whenever
ofﬁcial guidelines (e.g. OECD, EMA and ICH) and quality systems (e.g. GLP, GMP, GCP and
applicable ISO systems) were followed, the applicant should indicate compliance.
9) Deviations from the requirements speciﬁed in the respective sections described in this guidance
should be justiﬁed.
10) The decision on conﬁdential treatment of information submitted under Article 23 of Regulation
(EU) 2015/2283 falls under the responsibility of the European Commission. As per Article 23(5)
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of the Regulation, EFSA shall take necessary measures to ensure appropriate conﬁdentiality of
the information received under this Regulation, except for information which is required to be
made public in order to protect human health.
11) The decision on granting the protection of proprietary data under Article 26 of Regulation (EU)
2015/2283 falls under the responsibility of the European Commission. With respect to the
handling and use of proprietary data by EFSA, it should be noted that where evidence for the
safety of a novel food includes a request for the protection of proprietary data, the NDA
Panel considers in its opinion whether the safety of the novel food could have been assessed
without the data claimed as proprietary by the applicant or not.
12) In accordance with Directive 2010/63/EU4 on the protection of animals used for experimental
and other scientiﬁc purposes, and as reiterated in Regulation (EU) 2015/2283, tests on animals
should be replaced, reduced or reﬁned. Duplication of animal testing should be avoided, where
possible.
Organisation and content of the application
The following information should be provided in the application and the structure should follow a
common format. Data provided in the application should be organised into three parts:
• Part 1 contains the administrative data, such as information relating to the applicant.
• Part 2 contains information speciﬁc to the novel food with respect to identity of the novel food
(Section 2.2), production process (Section 2.3), compositional data (Section 2.4), speciﬁcations
(Section 2.5), the history of use of the novel food and/or of its source (Section 2.6), proposed
uses and use levels and anticipated intake (Section 2.7), absorption, distribution, metabolism
and excretion (Section 2.8), nutritional information (Section 2.9), toxicological information
(Section 2.10) and allergenicity (Section 2.11). It should include a list of all references.
• Part 3 comprises the glossary or abbreviations of terms quoted throughout the dossier, the
certiﬁcates (on the accreditation of laboratories, certiﬁcates of analyses) and contains full
copies/reprints of all pertinent scientiﬁc data (published and unpublished), full study reports,
and scientiﬁc opinions of national/international regulatory bodies.
1. Part 1: Administrative data
1.1. Comprehensive table of contents of the dossier
1.2. Applicant
1.2.1. Company/organisation
Provide the name and address of the company or organisation.5
1.2.2. Contact person
Indicate the contact person authorised to communicate with EFSA on behalf of the applicant.6
1.3. Regulatory status outside the European Union
If the novel food has been submitted by the applicant to a regulatory body for authorisation
outside the EU, please indicate the status of the evaluation by each regulatory body (if more than
one), as appropriate:
□ Under consideration
Specify the proposed conditions of use (if they are different), the date of submission, and the
recipient regulatory body.
4 Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used
for scientiﬁc purposes, OJ L 276, 20.10.2010, p. 33.
5 In case more than one company or organisation submits a dossier, provide their names and addresses. Only one contact
person should be authorised to communicate with EFSA.
6 To facilitate communication, only one contact person should be indicated per dossier.
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□ Withdrawn
Specify the conditions of use (if they are different) of the novel food which was withdrawn, the
date of withdrawal, the reasons for withdrawal. Indicate the regulatory body at the time of withdrawal.
□ Authorised
Specify the conditions of use (if they are different) of the novel food which has been approved, the
date of approval. Indicate the authorising regulatory body, and if available, provide a copy of the
scientiﬁc opinion of the regulatory body which authorised the novel food (in Part 3).
□ Rejected
Specify the date and the reasons of rejection. Indicate the regulatory body which rejected the
novel food, and if available, provide a copy of the scientiﬁc opinion of the regulatory body which
rejected the novel food (in Part 3).
2. Part 2: Characterisation of the novel food, technical and scientiﬁc
data
2.1. Introduction
The novel food should be brieﬂy described in an introductory paragraph, including the source, the
principle of the production process and typical compositional features. Its purpose and intended use
should be described.
2.2. Identity of the novel food
Information on the identity of the novel food should be provided, depending on the class(es) under
which the novel food falls. The Panel notes that the proposed classiﬁcation is based on the chemistry,
production process and source of novel foods, for the purpose of the scientiﬁc assessment, and is not
meant to reﬂect the regulatory categories outlined in Article 3(2)a of the Regulation. There may be
cases where a novel food could be allocated to two or more classes (e.g. ‘chemical substances’ and
‘food produced by a microorganism’). In such cases, the relevant information for all applicable classes
should be provided.
2.2.1. Chemical substances
• Chemical name, when appropriate, according to IUPAC nomenclature rules
• CAS number (if this has been attributed) and other identiﬁcation numbers
• Synonyms, trade names, abbreviations
• Molecular and structural formulae; stereochemistry
• Molecular mass (Da)
2.2.2. Polymers
• Structural formulae of monomers and starting materials, reagents involved in the polymerisation
• Structure of the polymer, number average molecular weight and weight average molecular weight
• Nature and degree of modiﬁcation of the polymer
• Particle size, shape and distribution
2.2.3. Foods consisting of, isolated from or produced from microorganisms, fungi
or algae
• Scientiﬁc (Latin) name (family, genus, species, strain) according to the international codes of
nomenclature
• Synonyms that may be used interchangeably with the preferred scientiﬁc name
• For algae7 and fungi,8 veriﬁcation of the identity according to internationally recognised
databases and methodology
7 For algae species: The Algae database (www.algaebase.org)
8 For the identiﬁcation of fungi: The Index fungorum: http://www.indexfungorum.org/names/names.asp for identiﬁcation of
fungi.
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• For bacteria and yeasts (unicellular organisms), veriﬁcation of the species and strain identity
according to internationally accepted methods; information on applicable methods for the
characterisation of bacteria and yeasts are provided in the EFSA Health Claim guidance (EFSA
NDA Panel, 2016b). Molecular methods allow predictions of genes encoding for toxins,
antimicrobial resistance and other pathogenic factors
• Origin of the organism
• If available, deposition in an ofﬁcially recognised culture collection with access number
2.2.4. Food consisting of, isolated from or produced from material of mineral
origin
This section concerns inorganic mineral constituents isolated from rocks and utilised as inorganic or
organic salts or chelates.
• Chemical name according to IUPAC nomenclature rules
• CAS number (if this has been attributed) and other identiﬁcation numbers
• Synonyms, trade names, abbreviations
• Molecular and structural formulae
• Molecular mass (Da)
• Particle size, shape, crystal form, distribution
2.2.5. Food consisting of, isolated from or produced from plants or their parts9
• Scientiﬁc (Latin) name (botanical family, genus, species, subspecies, variety with author’s
name, chemotype, if applicable) according to the international codes of nomenclature
• Synonyms (botanical name) that may be used interchangeably with the preferred scientiﬁc
name
• For plants10 veriﬁcation of the identity according to internationally recognised databases and
methodology
• Common names (if a trivial or a common name is used, it should be linked to the scientiﬁc
name and part used)
• Part(s) used (e.g. root, leaf, seed, etc.)
• Geographical origin (continent, country, region)
2.2.6. Food consisting of, isolated from or produced from animals or their parts
• Scientiﬁc (Latin) name (zoological family, genus, species, subspecies, breed, if applicable)
• Synonyms that may be used interchangeably with the preferred scientiﬁc name
• Common names (if a trivial or a common name is used, it should be linked to the scientiﬁc
name and part used)
• Part(s) used
• Geographical origin (continent, country, region)
2.2.7. Foods consisting of, isolated from or produced from cell culture or tissue
culture derived from animals, plants, fungi or algae
This section concerns cultures derived from multicellular origin (animals, plants including algae and
mushrooms). Foods originating from cultures of unicellular origin should be addressed under 2.2.3.
• Biological source (taxonomic information on family, genus, species, subspecies, variety)
according to the international codes of nomenclature
• For plants,10 algae7 and fungi,8 veriﬁcation of the identity according to internationally
recognised databases and methodology
• Organ and tissue or part of the organism sourced
• Laboratory or culture collection sourced
9 These requirements are in line with the EFSA Scientiﬁc Committee guidance on the safety assessment of botanicals and
botanical preparations intended for use as ingredients in food supplements (EFSA Scientiﬁc Committee, 2009a).
10 The Plant List (www.theplantlist.org) resulting from the Collaboration between the Royal Botanic Gardens, Kew and Missouri
Botanical Garden; The USDA-ARS Germplasm Resources Information Network (GRIN) database (https://npgsweb.ars-grin.gov/
gringlobal/taxon/taxonomysimple.aspx) in case The Plant List does not provide the required information; The International
Plant Names Index (http://www.ipni.org/) in case the two above sources do not provide the required information.
Guidance on novel foods
www.efsa.europa.eu/efsajournal 11 EFSA Journal 2016;14(11):4594
• Information on the identity of cells
• Cell or tissue substrate used as a novel food
• Type of cultures
2.2.8. Foods consisting of ‘engineered nanomaterials’11
For novel foods containing or consisting of ‘engineered nanomaterials’, the parameters for
characterisation and identiﬁcation of engineered nanomaterials are outlined in the EFSA Scientiﬁc
Committee guidance on the risk assessment of the application of nanoscience and nanotechnologies in
the food and feed chain (EFSA Scientiﬁc Committee, 2011a). The Panel notes that the guidance is
currently being updated by EFSA (EFSA-Q-2016-0028112).
2.3. Production process
2.3.1. Detailed description of the production process
The process(es) employed to produce the novel food (e.g. chemical synthesis, enzyme-catalysis,
fermentation or isolation from a natural source, etc.) should be described. The description of the
production process should be detailed enough to provide the information that will form the basis for
the evaluation of the bioavailability, nutritional value and safety, which should be addressed in the
respective sections. With regard to safety, the description should include information on potential
by-products, impurities or contaminants.
The applicant should inform whether a production process is novel, i.e. not used for food
production within the Union before 15 May 1997, and characterise the novel aspects of the process.
Information should also be provided on the handling of the sources, for example, the propagation,
growth and harvesting conditions for plants and fungi (e.g. wild or cultivated, cultivation practices,
time of harvest in relation to both season and stage of the plant growth); the breeding, rearing,
feeding and farming conditions for farmed animals or the hunting, catching or collecting and killing of
wild living animals; the culture conditions for microorganisms and algae, and cell culture or tissue
culture from plants and animals. The description of the cultivation of plants, fungi, algae and
microorganisms and the rearing of animals should also include information on the use of pesticides,
antimicrobials and antiparasitic agents.
Post-harvest handling, e.g. transport, drying techniques and storage conditions (duration, light,
moisture and temperature) of unprocessed foods and the raw materials for further processing should
be described. The parts of the organism used as a raw material should be speciﬁed and information on
other starting substances or materials should be provided.
For novel foods consisting of, isolated from or produced from plant, animal or microbiological
sources, the applicant should describe in detail the process by which the raw material is converted into
an ingredient or a preparation intended for a food product. Examples may include heat treatment,
extraction, distillation, squeezing, fractionation, puriﬁcation, concentration, fermentation, or other
procedure(s). Information on substances used in the manufacturing process, e.g. identity of the
extraction solvents, ratio of extraction solvent to the material, reagents, residues remaining in the ﬁnal
product and any special precautions (light and temperature) should be provided.
For novel foods obtained via chemical synthesis, the reaction sequence, side reactions and
puriﬁcation steps should be described. Information on reaction conditions (e.g. reagents, temperature,
duration of the reaction, and catalyst), chemical or physical puriﬁcation methods (e.g. solvent
extraction and crystallisation) should be reported.
Operational limits and key parameters of the production process should be given. Measures
implemented for production control and quality and safety assurance should be described (e.g. HACCP,
GMP, ISO). A production ﬂow chart should be provided, including quality and safety control checks.
Standardisation criteria (e.g. chemical markers for the novel food) should be provided.
For novel foods consisting of, isolated from or produced from plants-speciﬁc considerations and
complementary information are provided in the EFSA guidance on safety assessment of botanicals and
botanical preparations (EFSA Scientiﬁc Committee, 2009a).
11 As deﬁned in Regulation (EU) 2015/2283.
12 http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-2016-00281
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2.3.2. Non-conﬁdential description of the production process
If the detailed description on the production process (Section 2.3.1) contains conﬁdential elements,
the applicant is asked to provide a non-conﬁdential summary of the production process of between
half to a maximum of a page in length.
2.4. Compositional data
The information should include qualitative and quantitative data on the composition as well as
physicochemical, biochemical properties and microbiological characterisation of the novel food.
Section 2.4.1 outlines general data requirements applicable to all novel foods. Sections 2.4.2 and
2.4.3 set speciﬁc requirements depending on whether the novel food is a single substance or a simple
mixture thereof, a complex mixture or a whole food.13
Validated methods should be used for the analyses, preferably nationally or internationally
recognised methods (e.g. Association Of Analytical Communities, American Chemical Society, European
Pharmacopoeia). The respective methods of analysis should be described together with their
references. The information on analyses for substances of toxicological concern should also include
their limit of detection and limits of quantiﬁcation. Certiﬁcates of analyses and information on the
accreditation of laboratories should be provided. If in-house methods are employed, they should be
fully described, and the results of the respective validation procedures should be provided. If the
analyses are not performed in accredited laboratories, justiﬁcation should be provided. Analytical data
from publications can also be used if the publications provide sufﬁcient information on the laboratory
where analyses have been carried out, the methods utilised, and if the studies were performed on
representative samples of the novel food. Available published data can also contribute to provide
information on the variability of the composition of the novel food.
Compositional data and their variability should support the setting of speciﬁcations of the novel
food how it is intended to be placed on the market (Section 2.5). The analytical information should be
provided preferably on at least ﬁve representative batches of the novel food that have been
independently produced (i.e. with independent batches of raw materials). When several production
processes are proposed, such data should be provided for each process.
2.4.1. General requirements
Information on the identities and the quantities of impurities or by-products, residues and chemical
and microbiological contaminants should be provided (e.g. heavy metals, mycotoxins, PCBs/dioxins,
pesticides). The type and spectrum of potential target analytes should be considered in the light of the
sources and the production process. For example, for substances obtained by chemical synthesis,
residual starting materials and by-products anticipated from side-reactions should be analysed; for
substances produced by microbial fermentation, the presence of undesirable metabolites should be
investigated; for substances isolated by extraction, data on residues of the solvent used should be
provided.
2.4.2. Single substances and simple mixtures thereof
Simple mixtures are mixtures whose components can be fully chemically characterised. For simple
mixtures of deﬁned substances, information on the identities and the relative ratios of all components
should be provided. This should allow the elaboration of a mass balance.
For single substances, the following data should be provided:
• Identity tests (e.g. UV-VIS, IR, NMR, GC–MS, LC–MS)
• Physicochemical properties (e.g. appearance, melting point, boiling point)
• Solubility data in water and other common solvents
• Particle size, shape and distribution
• Minimum purity value
• Density and/or viscosity for liquid preparations
For single substances and their mixtures produced with genetically modiﬁed microorganisms
(GMMs), applicants are referred to the requirements for GMMs Category 1 (i.e. chemically deﬁned
puriﬁed compounds and their mixtures in which both GMMs and newly introduced genes have been
13 As deﬁned by the Scientiﬁc Committee (EFSA Scientiﬁc Committee, 2011a), https://www.efsa.europa.eu/en/efsajournal/pub/2438
Guidance on novel foods
www.efsa.europa.eu/efsajournal 13 EFSA Journal 2016;14(11):4594
removed, e.g. amino acids, vitamins) as laid down by the EFSA guidance on the risk assessment of
GMMs and their products intended for food and feed use (EFSA GMO Panel, 2011).
2.4.3. Complex mixtures and whole foods
Complex mixtures (e.g. extracts, protein hydrolysates) and whole foods (e.g. milk, meat, fruits,
seeds) are deﬁned as those where all constituents cannot be fully chemically characterised and/or
identiﬁed.
A qualitative and quantitative characterisation of the main constituents should be performed, at
least via sum parameters. For whole foods, this should include proximate analyses (i.e. ash, moisture,
protein, fat, carbohydrates). On the basis of these data, a mass balance should be calculated. The
amount of unidentiﬁed components should be indicated and should be as low as possible.
For the classes of naturally or chemically derived components which characterise the nature of the
novel food (e.g. peptides, phospholipids, carotenoids, phenolics, sterols), comprehensive qualitative
and quantitative data should be provided.
Qualitative and quantitative data on nutritionally relevant inherent constituents (e.g. micronutrients)
should be given.
Taking into account the source of the novel food, qualitative and quantitative data on inherent
substances of possible concern to human health (e.g. toxic, addictive, psychotropic, allergenic) should
be provided).
In addition to analytical data on composition analysis data, a literature search should be performed
according to the methodology developed by EFSA (2010) to retrieve published compositional data for
the source and the part used in/as novel food. Information on the used keywords and applied
inclusion/exclusion criteria for the literature search should be provided.
Any substances of concern derived from plants should be classiﬁed according to their chemical
structure. Levels at which the constituents are present in the respective part of the botanical or
botanical preparation should be given where available. It is recommended that chemical ﬁngerprinting
of the botanical material is undertaken for this purpose.
Particular attention should be given to the possible presence of genotoxic and/or carcinogenic
substances.
The following non-exhaustive tools can help identifying the possible substances of concern in a
botanical material:
• The EFSA Compendium of Botanicals, which provides information on naturally occurring
substances that may be of concern for human health (EFSA Scientiﬁc Committee, 2012a),14
• The EFSA Chemical Hazard Database (S-IN, 2015).
For complex mixtures produced with genetically modiﬁed microorganisms (GMMs), applicants are
referred to the requirements for GMMs Category 2 (i.e. complex products in which both GMMs and
newly introduced genes are no longer present, e.g. cell extracts, most enzyme preparations) as laid
down by the EFSA guidance on the risk assessment of GMMs and their products intended for food and
feed use (EFSA GMO Panel, 2011).
2.4.4. Stability
The stability of the novel food should be evaluated in order to identify hazards which might arise
during storage and transport. The nature of degradation products should be characterised.
Stability tests should consider constituents and parameters of the novel food which may be
susceptible to changes during storage and which may affect its safety or serve as indicators for
alterations which could have an impact on the safety of the novel food.
Depending on the nature and type of the novel food, the testing should address the
physicochemical, biochemical and microbiological stability of the novel food under normal conditions of
storage including the effects of packaging, the storage temperature and the environment (light, oxygen,
moisture, relative humidity). Information on the normal storage conditions of the novel food should be
provided as well as on the storage conditions under which the stability testing was performed. The
stability testing should be provided on preferably at least ﬁve representative batches of the novel food
that have been independently produced (i.e. with independent batches of raw materials).
14 https://www.efsa.europa.eu/en/data/compendium-botanicals
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The duration of the stability testing may depend on the type of the novel food and its proposed
uses and should cover at least the end of the shelf-life. Accelerated conditions (usually at higher
temperature) may be used as an alternative to stability testing under normal conditions.
If the novel food is used as an ingredient added to other foods, its stability in the processed foods
should be investigated in real foods or in relevant model systems (e.g. effect of processing
temperature, pH and other constituents in the processed foods).
Information on ingredients added to the novel food to improve its stability should be provided.
2.5. Speciﬁcations
The speciﬁcations deﬁne the key parameters that characterise and substantiate the identity of the
novel food, as well as the limits for these parameters and for other relevant physicochemical,
biochemical or microbiological parameters. The speciﬁcations will be used as key parameters, among
other compositional data, to evaluate whether the data provided to demonstrate the safety are
relevant to the novel food intended to be placed on the EU market. In addition, the limits set in the
speciﬁcations for toxicologically and/or nutritionally relevant components will be considered in the risk
assessment.
On the basis of the analytical data on the novel food provided in Sections 2.2–2.4, the applicant
should propose speciﬁcations, in the form of a table, which should include the limits and information
on the exact method for each of the selected parameters.
The speciﬁcations should include nutritional or biologically active components or, when these are
not known, on selected chemical markers. The speciﬁcations should also include concentrations of the
major groups of constituents present in the food including, for example, amino acids and proteins,
lipids, carbohydrates, inorganic ions, polyphenols, alkaloids, terpenes, alkenylbenzenes, lignin,
saponins, chitin, as well as the main substances within these classes.
A rationale for the selected parameters should be provided. As a minimum, the speciﬁcation should
include contents and/or limits for the parameters on the identity of the product; the minimal purity;
and limits acceptable for impurities and degradation products, in particular those of toxicological or
nutritional relevance. In the absence of legal requirements in the EU, maximum levels of contaminants
(e.g. microorganisms, mycotoxins, heavy metals, pesticide residues, polycyclic aromatic hydrocarbons)
should be included.
2.6. History of use of the novel food and/or of its source
2.6.1. History of the source
Data on the composition, production and on the experience from use of products from the source
(other than the novel food itself) may provide relevant aspects for further consideration, for example,
regarding critical substances contained in the source, potential hazards or precautions. With respect to
foods derived from plants, relevant information may be found in EFSA’s Compendium on Botanicals
(EFSA Scientiﬁc Committee, 2012a).
2.6.2. History of use of the novel food
Data may be available on the use of the novel food as food in countries outside of the EU and on
non-food uses. Such data may provide information which could be relevant for assessing the safety of
the novel food.
Such information could include a description of the extent of use as a food and/or for non-food
purposes, the population group for which the food has been a part of their diet, its role in the diet, the
handling and preparation of the food and on precautions of use. A comprehensive literature review of
human studies reporting on relevant safety outcomes should be performed. Information on the search
strategy, including the sources used to retrieve pertinent data (databases, other sources), the terms
and limits used (e.g. publication dates, publication types, languages, population, default tags) should
be provided. Where applicable, the published literature should be reviewed by taking into account
systematic review principles (EFSA, 2010). Full study reports should be provided if available.
The applicant should not only consider and limit the literature search to the novel food itself, but
should also consider searching for studies with speciﬁc and safety-relevant components of the novel
food and for studies with similar foods from the same or other closely related sources (e.g. other
varieties or subspecies or related species of the same genus or family).
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Available information on the consumption of a novel food as part of an ingredient or compound in
another food should be provided in Section 2.7.4.
2.7. Proposed uses and use levels and anticipated intake
Estimated intakes of the novel food for the European population are needed to evaluate its dietary
and nutritional signiﬁcance and to carry out the risk characterisation. Intakes are estimated based on
the proposed use levels of the novel food and data on actual food consumption.
A rationale for the target population, proposed uses and use levels, precautions and restrictions of
use should be provided, with cross-referencing to relevant safety data.
Where potential health hazards have been identiﬁed on the basis of the composition, toxicological
or other data, they should be discussed and adequately addressed in the proposed conditions of use
to ensure that the consumption of the novel food is safe for the target population.
It is of utmost importance that the information provided in this section is precise, complete, and
free of ambiguity because the safety of the novel food will be assessed under the proposed conditions
of use. If information provided in this section conﬂicts with information relating to conditions of use in
any other part of the dossier, priority will be given to the information provided in this section.
2.7.1. Target population
The applicant should unambiguously specify the intended target population, e.g. adults, the general
population or certain deﬁned population subgroups.
2.7.2. Proposed uses and use levels
The applicant should specify:
• the form of uses (e.g. as whole food, ingredient);
• the food categories15 in which the novel food (if an ingredient) is proposed to be used;
• whether the novel food is intended to replace another food;
• the proposed maximum amounts in product(s) as consumed;
• the proposed average and maximum daily intakes for different age/gender groups as
appropriate.
2.7.3. Anticipated intake of the novel food
On the basis of the information provided in Section 2.7.1 and 2.7.2, estimations of anticipated daily
intakes of the novel food are required (per kg body weight and in absolute amounts). Estimations of
mean and high (at least 95th percentile) anticipated daily intakes of the novel food are requested for
each target population group (including, where relevant vulnerable groups such as children, pregnant
and lactating women). The concurrent consumption of all food categories in which a novel food
ingredient is proposed to be used should be addressed in the estimations, possibly considering different
consumption scenarios. The highest estimated daily intake (i.e. at least the 95th percentile) among the
population groups from a representative database (e.g. EFSA Comprehensive European Food
Consumption Database or national dietary surveys) is recommended to be used as the starting point for
the safety evaluation. For the intake assessment on the basis of ‘per kg body weight’, the EFSA guidance
on default values and rounding should be taken into account (EFSA Scientiﬁc Committee, 2012b).
Chronic intake estimates should be provided by default. In case the available data from toxicological or
human data raise concerns regarding an acute effect, acute intake estimates should also be considered.
The application should document the methodological aspects of the intake assessment; in
particular:
• the sources of data used (sources of food consumption data and food composition data);
• the scientiﬁc principles and methods applied;
• the assumptions made and their rationale; in particular with respect to the assignment of a
food to a particular food category, or with respect to the model used for the calculation of high
intake levels.
15 Preferably the EFSA Food classiﬁcation system should be used (EFSA, 2011b).
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The Panel proposes a tiered approach where the ﬁrst step makes use of the summary statistics of
the EFSA Comprehensive Food consumption Database.16
Summary statistics of food consumption are available on the EFSA website in the form of
spreadsheets. Detailed information on the database and guidance on its use have been published by
EFSA (EFSA, 2011a). Anticipated daily intakes for mean and high-percentile consumers can be
calculated through the combination of the intended use level in each food category with mean and
high chronic consumption values from the database, respectively.
The use of the EFSA Food Additive Intake Model (FAIM) tool17 (which is also based on summary
statistics of the EFSA Comprehensive Food Consumption Database) may serve as an appropriate
alternative in tier 1. The FAIM tool was developed to support the calculation of chronic exposure to
food additives in the regulatory framework of food additives Regulation (EU) 1333/2008. Exposure
assessment of food additives and intake assessment of novel food ingredients share common
principles. Thus, the FAIM tool may be used by applicants for the intake assessment of novel foods
used as ingredients where the food categories to which the ingredient is intended to be added, match
reasonably with the food categories covered in the FAIM tool. It allows the applicant to estimate the
mean and high-level exposure to food ingredients for different population groups throughout several
European countries by means of pre-deﬁned exposure calculation worksheets. For the calculation of
high percentiles of daily intake, the model assumes that an individual might be a high-level consumer
of one food category only and would be an average consumer of all the remaining food groups. Thus,
the FAIM tool adds the highest of the high-levels of intake from one food category (calculated for
consumers only) to the mean intake values for the remaining categories (calculated for the total
population).
Summary statistics from the EFSA Comprehensive European Food Consumption Database (incl.
FAIM tool) provide valuable screening estimates of intake. In some cases, such estimates may bring
sufﬁcient information, if high intake estimates are below health-based guidance values (e.g. acceptable
or tolerable daily intake). In other cases, where more reﬁned estimates are needed, the applicant
should consider more detailed assessments, such as intake calculations based on individual data from
national food consumption surveys (tier 2).
The applicant should consider and discuss the uncertainties related to the assessment; in
particular, sources of under- or over-estimations. To this end, the guidance from the EFSA Scientiﬁc
Committee related to uncertainties in dietary exposure assessment should be considered (EFSA,
2006).
Where a novel food is intended to replace another food already existing on the market, the
applicant should provide their considerations and explanations why it is reasonable to expect that the
novel food would replace that food. In such cases, estimates of the consumption of the food that is
intended to be replaced could be used for estimating consumption of the novel food.
2.7.4. Combined intake from the novel food and other sources
Other potential sources of intake of the novel food should be taken into account (such as natural
occurrence in food). In such cases, an estimation of the mean and high daily intake of the constituent
from other sources should be considered, in order to assess the extent of the additional intake of the
constituent resulting from its intended use as a novel food, in relation to existing dietary intake.
Information should be provided on:
• mean and high daily intakes18 of the novel food from its proposed uses and maximum use
levels;
• mean and high daily intakes from natural sources (i.e. from the background diet);
• daily intake from food fortiﬁcation and supplements;
• daily intake from other uses.
For estimating total daily intake of the constituent, mean and high anticipated intakes from its
intended use as a novel food and current intake from background diet should be considered and
conservative scenarios should be applied.
16 http://www.efsa.europa.eu/en/food-consumption/comprehensive-database
17 https://www.efsa.europa.eu/sites/default/ﬁles/assets/faimtemplateinstructions.pdf and https://www.efsa.europa.eu/sites/default/
ﬁles/assets/faimtemplate.xls
18 ‘High daily intakes’ usually expressed by the 95th or 97.5th percentile.
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Any other potential non-dietary sources (e.g. from consumer products such as cosmetics, and from
pharmaceuticals) should also be considered and taken into consideration in the total exposure
assessment, where relevant.
2.7.5. Estimate of exposure to undesirable substances
Exposure estimates are also to be provided for relevant undesirable substances identiﬁed in the
compositional analysis, for example, potential secondary plant metabolites, residues, contaminants or
degradation products. These may be present in the novel food due to its source or the manufacturing
process, as well as due to its use and storage.
The same approach as that used for the intake estimate of the novel food should be followed, in
order to describe the anticipated exposure for average and high consumers to these constituents for
the relevant population groups.
2.7.6. Precautions and restrictions of use
When proposing precautions (including directions for its preparation and/or use) and restrictions of
use, all available information on safety should be taken into consideration.
The applicant should specify the population (sub)groups (including population groups with certain
physiological conditions) which should avoid consumption of the novel food and include the rationale.
2.8. Absorption, distribution, metabolism and excretion (ADME)
Data on absorption, distribution, metabolism and excretion (ADME) in humans and animals are
important for the assessment of both the nutritional and toxicological impact of a novel food.
Applicants are advised to consult the data requirements and tiered approach to kinetic testing
which are described in Section 4.1 on ‘Toxicokinetics (ADME)’ of the EFSA guidance for food additive
evaluations (EFSA ANS Panel, 2012). The Panel considers that the kinetics of single substances and
simple mixtures should normally be tested according to the same principles as those applied to food
additives. As a default, absorption of the novel food or its breakdown products should be assessed
(tier 1). Demonstration of negligible absorption may provide a scientiﬁc justiﬁcation for not
undertaking higher tiered toxicological studies.
For food additives in the form of complex mixtures, the ANS guidance states that
‘conventional metabolism and toxicokinetic studies may not be feasible for all components in the
mixture, but should be provided for toxicologically relevant constituents. Toxicologically relevant
constituents are generally considered to be the major components and those other components
with known or demonstrable biological or toxicological activity, and should be determined on a case-
by-case basis with a scientiﬁc justiﬁcation and the rationale for their selection provided’.
Whole foods should be tested like complex mixtures. The design of kinetic studies may be modiﬁed
based on the particular complex mixture/whole food being tested.
For novel foods, ADME assessment should also address nutritionally signiﬁcant constituents where
kinetic data on these constituents are important considerations for the evaluation of the nutritional
impact of the novel food (Section 2.9).
With respect to novel foods consisting of ‘engineered nanomaterials’, applicants should consider the
speciﬁc requirements and follow the approach as set out in the EFSA Scientiﬁc Committee guidance on
the risk assessment of the application of nanoscience and nanotechnologies in the food and feed chain (in
particular, sections on in vitro digestion studies and ADME studies) (EFSA Scientiﬁc Committee, 2011a).
The Panel notes that this EFSA guidance is currently being updated by EFSA (EFSA-Q-2016-0028112).
2.9. Nutritional information
The applicant should demonstrate that the novel food is not nutritionally disadvantageous for
consumers under the proposed conditions of use. For this purpose, in the context of this guidance, the
term nutritional information speciﬁcally refers to the role that the novel food may play in the diet in
terms of its contribution to or interaction with nutrient intakes.
Nutritional information on the novel food should include details of its nutrient composition and
address bioavailability taking into account inﬂuences of the production process, storage and further
processing that may be required prior consumption. In some cases, i.e. where cooking is necessary for
the intended use, e.g. to reduce or inactivate antinutritional substance, such effects should be
Guidance on novel foods
www.efsa.europa.eu/efsajournal 18 EFSA Journal 2016;14(11):4594
discussed by the applicant. The content and effect of antinutritional factors in the novel food (e.g.
inhibiting absorption or modifying bioavailability) and other known and suspected interactions with
nutrients should also be assessed.
Levels of use and estimated intakes for the target population should be taken into account as
speciﬁed in Section 2.7 (‘Proposed uses and use levels and anticipated intake of the novel food’).
Intakes of relevant substances from the background diet, both nutritional and antinutritional, should
be considered for establishing mean and high daily intake scenarios. The resulting estimates should be
discussed in the context of available dietary reference values including tolerable upper intake levels
(‘upper levels’). Intake estimates for potentially antinutritional substances should be compared with
health-based guidance (e.g. ADI) values, if available. Vulnerable subgroups such as young children,
pregnant and lactating women or subjects with particular metabolic or physiological characteristics
should be speciﬁcally considered on a case-by-case basis. Where a novel food is intended to replace
another food, or when a novel production process is applied to a food which is a relevant source for
nutrients, the applicant should demonstrate that the novel food does not differ in a way that it would
be nutritionally disadvantageous for the consumer under the proposed conditions of use.
Apart from an evaluation of the compositional data and an appraisal of the relevant literature and
databases, in speciﬁc cases, data from investigations in in vitro and/or in animal models and/or human
studies may be needed to address the interaction of the novel food with the diet and nutrients. The
necessity for such studies may arise from information on the source, the composition and the
production of the novel food, from documented experience on the uses, preparation and/or handling
of the novel food (e.g. foods which have been consumed in third countries), outcomes from studies on
ADME, and from pharmacological, mechanistic, feeding, toxicological and human studies.
2.10. Toxicological information
2.10.1. General considerations
Toxicological studies should be carried out with the novel food as intended to be marketed, i.e. the
test material should be manufactured according to the production process described in Section 2.3,
meet the compositional characteristics provided in Section 2.4 and meet the speciﬁcations proposed in
Section 2.5. If this is not the case, a rationale should be provided to substantiate why the test material
used for the toxicological studies is appropriate for the safety assessment of the novel food.
Toxicological studies should be conducted in accordance with international guidelines (e.g. OECD)
and according to the principles of GLP.
The Panel notes that all relevant knowledge on the novel food should be considered in order to
make decisions on whether and which toxicity studies are necessary. Important elements include:
• the identity, chemical structure, composition and physico-chemical properties of the novel food
(Sections 2.1–2.5);
• available information on previous human consumption of the novel food and its source
(Section 2.6);
• anticipated use(s), maximum use levels and the resulting intakes (Section 2.7);
• available kinetic data (Section 2.8);
• available toxicological data on the novel food or its constituents;
• available human studies;
• available relevant information on non-food uses (e.g. cosmetics, chemicals, pharmaceuticals);
• in case of insufﬁcient experimental data also: (quantitative) structure–activity relationship
((Q)SAR) data.
Toxicological data on structurally related substances (‘read-across’) should be considered. The
Panel considers that the tiered toxicity testing approach proposed for food additives should be
considered as the default approach. It integrates the core areas of kinetics, genotoxicity, repeated
dose toxicity testing (subchronic, chronic toxicity and carcinogenicity) and reproductive and
developmental toxicity (EFSA ANS Panel, 2012). Additional studies may be needed to examine speciﬁc
biological processes which may not be fully considered in the core areas for evaluation. Other studies
that may be relevant include, e.g. immunotoxicity, hypersensitivity and food intolerance, studies on
neurotoxicity, endocrine activity and mode of action.
Deviations from this approach and/or its non-applicability should be reasoned with sound scientiﬁc
arguments based on the elements listed in the bullet points above.
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The types and purposes of toxicity studies are outlined in Sections 2.10.2–2.10.6 of the present
guidance for novel food applications. Speciﬁc cases are described in Section 2.10.7.
The Panel notes that the Threshold of Toxicological Concern (TTC) approach might be helpful when
assessing the risk of low exposure to substances such as impurities, metabolites and degradation products
present in (or derived from) the novel food for which toxicity data may not be available. The applicant is
advised to consult the EFSA guidance on the concept of TTC (EFSA Scientiﬁc Committee, 2012c).
2.10.2. Genotoxicity
The assessment of genotoxic potential is a basic component of chemical risk assessment (EFSA
Scientiﬁc Committee, 2011b). Genotoxicity testing of novel foods should aim at identifying substances
which could cause heritable damage in humans, and at predicting potential genotoxic carcinogens in
cases where carcinogenicity data are not available.
The Scientiﬁc Committee recommended a step-wise (tiered) approach for the generation and
evaluation of data on genotoxic potential (EFSA Scientiﬁc Committee, 2011b). A basic battery of
in vitro tests is recommended as a ﬁrst step, and follow-up approaches in the event of positive results
from the basic battery are provided. Recommendations on test types, results interpretations and other
issues in testing the genotoxicity of substances present in food are described in detail in the Opinion of
the Scientiﬁc Committee.
The Panel notes that the approach proposed by the Scientiﬁc Committee in principle applies to
novel foods. For some complex mixtures and whole foods, it may be necessary to focus on speciﬁc
constituents of the novel food. Deviations can be argued on a case-by-case basis.
2.10.3. Subchronic toxicity
In line with the guidance for food additives, a subchronic toxicity study should normally be
submitted (EFSA ANS Panel, 2012). The major objective of such study is to identify any adverse effects
following prolonged exposure via an appropriate oral route.
It should also allow determination of the relevant BMDL (EFSA Scientiﬁc Committee, 2009b) or the
NOAEL. The subchronic toxicity study can provide indications on the need for additional studies on
speciﬁc effects (Sections 2.10.4–2.10.6).
The study should normally be conducted for a period of at least 90 days (OECD TG 408), modiﬁed
to include assessment of some additional parameters described in the more recent guideline on
repeated-dose 28-day oral toxicity studies in rodents (OECD TG 407). The additional parameters place
more emphasis on endocrine-related endpoints. The modiﬁed 90-day study should allow for the
identiﬁcation of substances with the potential to cause neurotoxic, immunological, reproductive organ
effects or endocrine-mediated effects. When kinetics testing indicates a lack of systemic availability,
studies should at least investigate both pathological and physiological effects in the gastrointestinal
tract. The effects of unabsorbed materials on gastrointestinal function and tolerance also need to be
investigated. Speciﬁc to novel foods, the Panel notes that additional markers of potentially adverse
nutritional and/or metabolic effects should be considered on a case-by-case basis, according to the
available body of evidence and the nature of the novel food.
For ‘whole foods’, the testing requirements should be determined using a case-by-case approach, as
special considerations are required with regard to dose selection and the avoidance of possible nutritional
imbalances. For further guidance on the conduction of subchronic oral toxicity studies with ‘whole foods’,
the applicant is advised to consult the relevant guidance from the Scientiﬁc Committee (EFSA Scientiﬁc
Committee, 2011c).
2.10.4. Chronic toxicity and carcinogenicity
Important considerations which can trigger the need for chronic toxicity or carcinogenicity studies
include, among others, critical ﬁndings in the subchronic study as well as results of in vitro or in vivo
toxicity tests, including genotoxicity tests. Further guidance on the triggers for these studies and their
implementation are outlined in the guidance on food additives (EFSA ANS Panel, 2012) and respective
OECD Guidelines (OECD TG 451, 452 or 453).
2.10.5. Reproductive and developmental toxicity
Decisions on whether tests for reproductive and developmental toxicity are necessary need to be
considered in the light of kinetic and toxicity data, including read-across data.
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Any indications of effects on reproductive organs or parameters, for example in the modiﬁed 90-
day oral toxicity, will trigger testing for reproductive and developmental toxicity. Reproductive and
developmental toxicity testing may not be required, if argued on a case-by-case basis.
2.10.6. Human data
Human studies, if available, should be provided if they contain information relevant for the safety
assessment, such as physical examination, blood chemistry, haematology, urine analysis, blood
pressure and organ function tests and/or monitoring of adverse reactions. Relevant data may be
derived from the use of the novel food for medical purposes or from epidemiological studies.
Additional human studies may be needed to investigate further potentially adverse effects, e.g. to
address adverse effects observed in toxicological studies. In those cases where the novel food may
exert pharmacodynamic effects, speciﬁc studies may be required to demonstrate that the proposed
consumption and use of the novel food do not raise safety concerns.
The data from intervention studies and observational studies in humans should be organised
according to a hierarchy of study designs and research questions, reﬂecting the relative strength of
evidence which may be obtained from different types of studies. Studies with the highest level of
scientiﬁc evidence should be presented ﬁrst.
2.10.7. Speciﬁc cases
2.10.7.1. Insects
The EFSA Scientiﬁc Committee has identiﬁed potential hazards related to the use of farmed insects as
food (EFSA Scientiﬁc Committee, 2015). These should be considered in applications for novel foods
which consist of, are isolated from, or are produced from farmed insects, taking into account the species
and substrate to be used, as well as methods for farming and processing. Insects collected from the wild
may bear additional biological and chemical hazards which should be considered and addressed.
2.10.7.2. Microorganisms
A wide variety of microorganisms and fungal species are used in food and feed production, either
directly (e.g. to produce fermented foods) or as sources of additives, food enzymes or other
components of foods. Many of them are present in high concentrations as viable microorganisms in
the ﬁnal product. Some of these microorganisms have a history of safe use and have been assigned
the qualiﬁed presumption of safety (QPS) status by EFSA which constitutes a preliminary safety
assessment (EFSA BIOHAZ Panel, 2015). This QPS list includes taxonomic groups that have not raised
safety concerns so far, and others for which some safety concerns exist but could be deﬁned and
addressed with ‘qualiﬁcation’ as expressed in the QPS list. Therefore, any strain of microorganism, the
identity of which could be unambiguously established and assigned to a QPS group, would be freed
from the need for an exhaustive safety assessment apart from satisfying the criteria and qualiﬁcations
speciﬁed previously (EFSA, 2008) and assessing the risk of antimicrobial resistance (EFSA FEEDAP
Panel, 2012).
For those microorganisms for which safety properties are less well understood, a safety assessment
should be provided. The safety assessment of microorganisms is primarily based on unambiguous
taxonomic classiﬁcation at species level and complete strain characterisation by fully assembled and
validated whole-genome sequence analysis to enable the detection of virulence-related genes,
antibiotic resistances and their potential horizontal transfer, and other potentially adverse metabolic
features (e.g. toxins, D-lactate, etc.). Phenotypic characterisation of the potential antimicrobial
resistances (intrinsic or acquired) should also be carried out following EFSA recommendations applying
to all microorganisms used in food or feed production (EFSA FEEDAP Panel, 2012). When appropriate,
depending on the taxonomic classiﬁcation and genome information of the microorganism, other
potentially adverse phenotypic features should be assessed (e.g. potential toxin production, haemolytic
activity, infectivity, adverse immune effects, etc.). For safety assessment, information should be
provided on the numbers of viable microorganisms in the ﬁnal product and stability.
2.10.7.3. Engineered nanomaterials
If the novel food is containing or consisting of ‘engineered nanomaterials’, the applicant should
consider the guidance on the risk assessment of the application of nanoscience and nanotechnologies
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in the food and feed chain from EFSA’s Scientiﬁc Committee (EFSA Scientiﬁc Committee, 2011a) which
is currently under review by EFSA (EFSA-Q-2016-0028119).
2.11. Allergenicity
Food allergens are mostly proteins. Hence, the allergenic potential of a novel food containing no
protein (or peptides) is very low. An accurate description of the methods used for the analysis of the
protein content in the novel food (including the limits of detection and quantiﬁcation) and the results
from those analyses should be provided in Section 2.4.
The default assumption for novel foods containing proteins is that they have allergenic potential.
The allergenic potential of the novel food should be explored by considering its composition,
particularly its protein(s), its source (including taxonomic relationships), the production process, and
available experimental and human data, including information on cross-reactivity. This comprises a
comprehensive literature review in order to retrieve available information on sensitisation, case reports
of allergic reactions, and/or allergenicity studies (in vitro, in animals, in humans) of the novel food
and/or its source(s).
Information on appropriate methods to further investigate the potential allergenicity of foods is
provided in the Scientiﬁc Opinion of the NDA Panel on the evaluation of allergenic foods and food
ingredients for labelling purposes (EFSA NDA Panel, 2014). Such methods include:
2.11.1. Protein analysis
• Protein content in the novel food,
• Molecular weight of the potentially allergenic protein, heat stability, sensitivity to pH,
digestibility by gastrointestinal proteases,
• Degree of sequence homology with known allergens,
• Immunological tests (e.g. western blotting).
2.11.2. Human testing
• Detection of speciﬁc IgE antibodies,
• Skin prick testing,
• Double-blind placebo-controlled food challenge studies.
If an applicant wishes to demonstrate that the novel food is unlikely to trigger adverse reactions in
sensitive individuals under the proposed conditions of use, the approach outlined in the EFSA guidance
on the preparation and presentation of applications pursuant to Article 6 Paragraph 11 of Directive
2000/13/EC, as amended (EFSA NDA Panel, 2013) should be followed.
Applicants for novel foods which potentially contain allergens listed in Annex II of Regulation (EU)
No 1169/2011 and who seek exemption from mandatory labelling are advised to ﬁle an application
pursuant to Article 21 paragraph 2 of Regulation 1169/2011 (previously Article 6 Paragraph 11 of
Directive 2000/13/EC) by using the afore-mentioned guidance document (EFSA NDA Panel, 2013).
2.12. Concluding remarks
The applicant should integrate the data presented in the previous sections to provide their overall
considerations on how the information supports the safety of the novel food under the proposed
conditions of use.
Where potential health hazards have been identiﬁed (e.g. on the basis of the composition of the
novel food, its production process, its history of use, the results from animal and/or human studies),
they should be discussed in relation to the anticipated intakes of the novel food and the proposed
target populations.
In particular, the applicant should address:
• the relevance of toxicologically relevant components (e.g. impurities, by-products, residues,
chemical or microbiological contaminants) in relation to their estimated intakes, possible
background exposure and their health-based guidance values (e.g. tolerable daily intakes),
when applicable;
• the results of toxicity studies;
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• any adverse effects identiﬁed through the human data;
• sources of uncertainties.
3. Part 3: Annexes to the dossier
• The glossary or abbreviations of terms quoted throughout the dossier,
• The certiﬁcates (on the accreditation of laboratories, certiﬁcates of analyses),
• Full copies/reprints of all pertinent scientiﬁc data (published and unpublished),
• Full study reports,
• Scientiﬁc opinions of national/international regulatory bodies.
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Abbreviations
ADI acceptable daily intake
ADME absorption, distribution, metabolism, excretion
BMDL lower conﬁdence limit for a benchmark dose
CAS Chemical Abstracts Service
EMA European Medicines Agency
FAIM Food Additive Intake Model
GC–MS gas chromatography–mass spectrometry
GCP Good Clinical Practice
GLP Good Laboratory Practice
GMM genetically modiﬁed microorganism
GMP Good Manufacturing Practice
HACCP Hazard Analysis Critical Control Point
ICH International Conference on Harmonisation
IR infrared spectroscopy
ISO International Organization for Standardization
IUPAC International Union of Pure and Applied Chemistry
LC–MS liquid chromatography–mass spectrometry
NDA EFSA Panel on Dietetic Products, Nutrition and Allergies
NMR nuclear magnetic resonance
NOAEL no adverse effect level
OECD Organisation for Economic Co-operation and Development
PCBs polychlorinated biphenyls
QPS qualiﬁed presumption of safety
(Q)SAR (quantitative) structure activity relationship
TTC threshold of toxicological concern
UV-VIS ultraviolet-visible spectroscopy
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